{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:11:27Z","timestamp":1793661087841,"version":"4.5.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"crossref","award":["2023ZY1014"],"award-info":[{"award-number":["2023ZY1014"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["2023KY210"],"award-info":[{"award-number":["2023KY210"]}]},{"name":"Hangzhou City \u201c115\u201d plan to introduce overseas intelligence projects","award":["202412171"],"award-info":[{"award-number":["202412171"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11030-025-11282-8","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T01:30:47Z","timestamp":1752975047000},"page":"1527-1551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Design, synthesis, and biological evaluation of aminopyrazine-based ATR\/HDACs dual inhibitors"],"prefix":"10.1007","volume":"30","author":[{"given":"Ying-Hui","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Long","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Lan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3211-8025","authenticated-orcid":false,"given":"Zi","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3739-0930","authenticated-orcid":false,"given":"Xiang-Yang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,20]]},"reference":[{"key":"11282_CR1","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.2174\/1381612822666160224142812","volume":"22","author":"W Zhang","year":"2016","unstructured":"Zhang W, Bai Y, Wang Y, Xiao W (2016) Polypharmacology in drug discovery: a review from systems pharmacology perspective. Curr Pharm Des 22:3171\u20133181. https:\/\/doi.org\/10.2174\/1381612822666160224142812","journal-title":"Curr Pharm Des"},{"key":"11282_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"AL Hopkins","year":"2008","unstructured":"Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4:682\u2013690. https:\/\/doi.org\/10.1038\/nchembio.118","journal-title":"Nat Chem Biol"},{"key":"11282_CR3","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.2174\/092986712801215883","volume":"19","author":"L Costantino","year":"2012","unstructured":"Costantino L, Barlocco D (2012) Designed multiple ligands: basic research vs clinical outcomes. Curr Med Chem 19:3353\u20133387. https:\/\/doi.org\/10.2174\/092986712801215883","journal-title":"Curr Med Chem"},{"key":"11282_CR4","doi-asserted-by":"publisher","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","volume":"62","author":"J Zhou","year":"2019","unstructured":"Zhou J, Jiang X, He S, Jiang H, Feng F, Liu W, Qu W, Sun H (2019) Rational design of multitarget-directed ligands: strategies and emerging paradigms. J Med Chem 62:8881\u20138914. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00017","journal-title":"J Med Chem"},{"key":"11282_CR5","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1021\/jm058225d","volume":"48","author":"R Morphy","year":"2005","unstructured":"Morphy R, Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48:6523\u20136543. https:\/\/doi.org\/10.1021\/jm058225d","journal-title":"J Med Chem"},{"key":"11282_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2174\/138161209787315594","volume":"15","author":"R Morphy","year":"2009","unstructured":"Morphy R, Rankovic Z (2009) Designing multiple ligands-medicinal chemistry strategies and challenges. Curr Pharm Des 15:587\u2013600. https:\/\/doi.org\/10.2174\/138161209787315594","journal-title":"Curr Pharm Des"},{"key":"11282_CR7","doi-asserted-by":"publisher","first-page":"100017","DOI":"10.1016\/j.crphar.2021.100017","volume":"2","author":"FM Barnieh","year":"2021","unstructured":"Barnieh FM, Loadman PM, Falconer RA (2021) Progress towards a clinically-successful ATR inhibitor for cancer therapy. Curr Res Pharmacol Drug Discov 2:100017. https:\/\/doi.org\/10.1016\/j.crphar.2021.100017","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"11282_CR8","doi-asserted-by":"publisher","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","volume":"5","author":"A Mar\u00e9chal","year":"2013","unstructured":"Mar\u00e9chal A, Zou L (2013) DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol 5:a012716. https:\/\/doi.org\/10.1101\/cshperspect.a012716","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"11282_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.currproblcancer.2017.05.002","volume":"41","author":"R Sundar","year":"2017","unstructured":"Sundar R, Brown J, Russo AI, Yap TA (2017) Targeting ATR in cancer medicine. Curr Probl Cancer 41:302\u2013315. https:\/\/doi.org\/10.1016\/j.currproblcancer.2017.05.002","journal-title":"Curr Probl Cancer"},{"key":"11282_CR10","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.3390\/molecules27082491","volume":"27","author":"LW Wang","year":"2022","unstructured":"Wang LW, Jiang S, Yuan YH, Duan J, Mao ND, Hui Z, Bai R, Xie T, Ye XY (2022) Recent advances in synergistic antitumor effects exploited from the inhibition of ataxia telangiectasia and RAD3-related protein kinase (ATR). Molecules 27:2491. https:\/\/doi.org\/10.3390\/molecules27082491","journal-title":"Molecules"},{"key":"11282_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13578-020-0376-x","volume":"10","author":"D Menolfi","year":"2020","unstructured":"Menolfi D, Zha S (2020) ATM, ATR and DNA-PKcs kinases-the lessons from the mouse models: inhibition \u2260 deletion. Cell Biosci 10:8. https:\/\/doi.org\/10.1186\/s13578-020-0376-x","journal-title":"Cell Biosci"},{"key":"11282_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/978-3-031-30065-3_14","volume":"186","author":"C Salguero","year":"2023","unstructured":"Salguero C, Valladolid C, Robinson HMR, Smith GCM, Yap TA (2023) Targeting ATR in cancer medicine. Cancer Treat Res 186:239\u2013283. https:\/\/doi.org\/10.1007\/978-3-031-30065-3_14","journal-title":"Cancer Treat Res"},{"key":"11282_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi NYL, Pili\u00e9 PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA (2024) Targeting ATR in patients with cancer. Nat Rev Clin Oncol 21:278\u2013293. https:\/\/doi.org\/10.1038\/s41571-024-00863-5","journal-title":"Nat Rev Clin Oncol"},{"key":"11282_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","volume":"14","author":"JH Hu","year":"2021","unstructured":"Hu JH, Cao JS, Topatana W, Juengpanich S, Li SJ, Zhang B, Shen JL, Cai LX, Cai XJ, Chen MY (2021) Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol 14:157. https:\/\/doi.org\/10.1186\/s13045-021-01169-0","journal-title":"J Hematol Oncol"},{"key":"11282_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RAM (2022) Cell cycle control in cancer. Nat Rev Mol Cell Biol 23:74\u201388. https:\/\/doi.org\/10.1038\/s41580-021-00404-3","journal-title":"Nat Rev Mol Cell Biol"},{"key":"11282_CR16","doi-asserted-by":"publisher","first-page":"11684","DOI":"10.3390\/ijms241411684","volume":"24","author":"H Biswas","year":"2023","unstructured":"Biswas H, Makinwa Y, Zou Y (2023) Novel cellular functions of ATR for therapeutic targeting: embryogenesis to tumorigenesis. Int J Mol Sci 24:11684. https:\/\/doi.org\/10.3390\/ijms241411684","journal-title":"Int J Mol Sci"},{"key":"11282_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-020-00874-6","volume":"13","author":"P Gralewska","year":"2020","unstructured":"Gralewska P, Gajek A, Marczak A, Rogalska A (2020) Participation of the ATR\/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer. J Hematol Oncol 13:39. https:\/\/doi.org\/10.1186\/s13045-020-00874-6","journal-title":"J Hematol Oncol"},{"key":"11282_CR18","doi-asserted-by":"publisher","first-page":"107518","DOI":"10.1016\/j.pharmthera.2020.107518","volume":"210","author":"L Gorecki","year":"2020","unstructured":"Gorecki L, Andrs M, Rezacova M, Korabecny J (2020) Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy. Pharmacol Ther 210:107518. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107518","journal-title":"Pharmacol Ther"},{"key":"11282_CR19","doi-asserted-by":"publisher","first-page":"101668","DOI":"10.1016\/j.isci.2020.101668","volume":"23","author":"E Bowler","year":"2020","unstructured":"Bowler E, Skwarska A, Wilson JD, Ramachandran S, Bolland H, Easton A, Ostheimer C, Hwang MS, Leszczynska KB, Conway SJ, Hammond EM (2020) Pharmacological inhibition of ATR can block autophagy through an ATR-independent mechanism. iScience 23:101668. https:\/\/doi.org\/10.1016\/j.isci.2020.101668","journal-title":"iScience"},{"key":"11282_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13045-019-0733-6","volume":"12","author":"L Mei","year":"2019","unstructured":"Mei L, Zhang J, He K, Zhang J (2019) Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol 12:43. https:\/\/doi.org\/10.1186\/s13045-019-0733-6","journal-title":"J Hematol Oncol"},{"key":"11282_CR21","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1021\/acs.jmedchem.9b00426","volume":"62","author":"R Knegtel","year":"2019","unstructured":"Knegtel R, Charrier JD, Durrant S, Davis C, O\u2019Donnell M, Storck P, MacCormick S, Kay D, Pinder J, Virani A, Twin H, Griffiths M, Reaper P, Littlewood P, Young S, Golec J, Pollard J (2019) Rational design of 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of intra- and intermolecular polar interactions of a new ataxia telangiectasia mutated and Rad3-related (ATR) kinase inhibitor. J Med Chem 62:5547\u20135561. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00426","journal-title":"J Med Chem"},{"key":"11282_CR22","doi-asserted-by":"publisher","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","volume":"61","author":"KM Foote","year":"2018","unstructured":"Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, Lau A, Blades K, Heathcote D, Odedra R, Wilkinson G, Wilson Z, Wood CM, Jewsbury PJ (2018) Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent. J Med Chem 61:9889\u20139907. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01187","journal-title":"J Med Chem"},{"key":"11282_CR23","doi-asserted-by":"publisher","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","volume":"63","author":"U L\u00fccking","year":"2020","unstructured":"L\u00fccking U, Wortmann L, Wengner AM, Lefranc J, Lienau P, Briem H, Siemeister G, B\u00f6mer U, Denner K, Sch\u00e4fer M, Koppitz M, Eis K, Bartels F, Bader B, Bone W, Moosmayer D, Holton SJ, Ebersp\u00e4cher U, Grudzinska-Goebel J, Schatz C, Deeg G, Mumberg D, von Nussbaum F (2020) Damage incorporated: Discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models. J Med Chem 63:7293\u20137325. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00369","journal-title":"J Med Chem"},{"key":"11282_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1535-7163.MCT-22-0685","volume":"22","author":"A Turchick","year":"2023","unstructured":"Turchick A, Zimmermann A, Chiu LY, Dahmen H, Elenbaas B, Zenke FT, Blaukat A, Vassilev LT (2023) Selective inhibition of ATM-dependent double-strand break repair and checkpoint control synergistically enhances the efficacy of ATR inhibitors. Mol Cancer Ther 22:859\u2013872. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0685","journal-title":"Mol Cancer Ther"},{"key":"11282_CR25","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","volume":"30","author":"TA Yap","year":"2024","unstructured":"Yap TA, Tolcher AW, Plummer R, Mukker JK, Enderlin M, Hicking C, Grombacher T, Locatelli G, Szucs Z, Gounaris I, de Bono JS (2024) First-in-human study of the ataxia telangiectasia and Rad3-related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors. Clin Cancer Res 30:2057\u20132067","journal-title":"Clin Cancer Res"},{"key":"11282_CR26","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1111\/cas.15845","volume":"114","author":"K Yano","year":"2023","unstructured":"Yano K, Shiotani B (2023) Emerging strategies for cancer therapy by ATR inhibitors. Cancer Sci 114:2709\u20132721","journal-title":"Cancer Sci"},{"key":"11282_CR27","doi-asserted-by":"publisher","first-page":"117834","DOI":"10.1016\/j.ejmech.2025.117834","volume":"296","author":"K Li","year":"2025","unstructured":"Li K, Sun X, Liu S, Liu Y, Feng X, Zhang G (2025) A medicinal chemistry perspective on ATR: current status and future directions. Eur J Med Chem 296:117834. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117834","journal-title":"Eur J Med Chem"},{"key":"11282_CR28","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaoncol.2021.3441","volume":"7","author":"SK Pal","year":"2021","unstructured":"Pal SK, Frankel PH, Mortazavi A, Milowsky M, Vaishampayan U, Parikh M, Lyou Y, Weng P, Parikh R, Teply B, Dreicer R, Emamekhoo H, Michaelson D, Hoimes C, Zhang T, Srinivas S, Kim WY, Cui Y, Newman E, Lara PN Jr (2021) Effect of cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma: a phase 2 randomized clinical trial. JAMA Oncol 7:1536\u20131543. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3441","journal-title":"JAMA Oncol"},{"key":"11282_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS (2021) First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov 11:80\u201391. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0868","journal-title":"Cancer Discov"},{"key":"11282_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1158\/1541-7786.MCR-20-0414","volume":"19","author":"K Ramkumar","year":"2021","unstructured":"Ramkumar K, Stewart CA, Cargill KR, Della Corte CM, Wang Q, Shen L, Diao L, Cardnell RJ, Peng DH, Rodriguez BL, Fan YH, Heymach JV, Wang J, Gay CM, Gibbons DL, Byers LA (2021) AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors. Mol Cancer Res 19:485\u2013497. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0414","journal-title":"Mol Cancer Res"},{"key":"11282_CR31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s43018-020-00171-8","volume":"2","author":"I Roeschert","year":"2021","unstructured":"Roeschert I, Poon E, Henssen AG, Garcia HD, Gatti M, Giansanti C, Jamin Y, Ade CP, Gallant P, Sch\u00fclein-V\u00f6lk C, Beli P, Richards M, Rosenfeldt M, Altmeyer M, Anderson J, Eggert A, Dobbelstein M, Bayliss R, Chesler L, B\u00fcchel G, Eilers M (2021) Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma. Nat Cancer 2:312\u2013326. https:\/\/doi.org\/10.1038\/s43018-020-00171-8","journal-title":"Nat Cancer"},{"key":"11282_CR32","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.2174\/1568026619666181210152115","volume":"18","author":"Y Sun","year":"2018","unstructured":"Sun Y, Sun Y, Yue S, Wang Y, Lu F (2018) Histone deacetylase inhibitors in cancer therapy. Curr Top Med Chem 18:2420\u20132428. https:\/\/doi.org\/10.2174\/1568026619666181210152115","journal-title":"Curr Top Med Chem"},{"key":"11282_CR33","doi-asserted-by":"publisher","first-page":"113946","DOI":"10.1016\/j.ejmech.2021.113946","volume":"227","author":"X He","year":"2022","unstructured":"He X, Hui Z, Xu L, Bai R, Gao Y, Wang Z, Xie T, Ye XY (2022) Medicinal chemistry updates of novel HDACs inhibitors (2020 to present). Eur J Med Chem 227:113946. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113946","journal-title":"Eur J Med Chem"},{"key":"11282_CR34","doi-asserted-by":"publisher","first-page":"114224","DOI":"10.1016\/j.bcp.2020.114224","volume":"182","author":"Y Gao","year":"2020","unstructured":"Gao Y, Zhang H, Lirussi F, Garrido C, Ye XY, Xie T (2020) Dual inhibitors of histone deacetylases and other cancer-related targets: a pharmacological perspective. Biochem Pharmacol 182:114224. https:\/\/doi.org\/10.1016\/j.bcp.2020.114224","journal-title":"Biochem Pharmacol"},{"key":"11282_CR35","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","volume":"26","author":"WS Xu","year":"2007","unstructured":"Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541\u20135552. https:\/\/doi.org\/10.1038\/sj.onc.1210620","journal-title":"Oncogene"},{"key":"11282_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/critrevoncog.2014012463","volume":"20","author":"H Olzscha","year":"2015","unstructured":"Olzscha H, Sheikh S, La Thangue NB (2015) Deacetylation of chromatin and gene expression regulation: a new target for epigenetic therapy. Crit Rev Oncog 20:1\u201317. https:\/\/doi.org\/10.1615\/critrevoncog.2014012463","journal-title":"Crit Rev Oncog"},{"key":"11282_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3389\/fcell.2020.00425","volume":"8","author":"LAM Kulka","year":"2020","unstructured":"Kulka LAM, Fangmann PV, Panfilova D, Olzscha H (2020) Impact of HDAC inhibitors on protein quality control systems: consequences for precision medicine in malignant disease. Front Cell Dev Biol 8:425. https:\/\/doi.org\/10.3389\/fcell.2020.00425","journal-title":"Front Cell Dev Biol"},{"key":"11282_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4103\/0973-1482.137937","volume":"10","author":"KC Lakshmaiah","year":"2014","unstructured":"Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D, Saldanha SC (2014) Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther 10:469\u2013478. https:\/\/doi.org\/10.4103\/0973-1482.137937","journal-title":"J Cancer Res Ther"},{"key":"11282_CR39","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","volume":"63","author":"TCS Ho","year":"2020","unstructured":"Ho TCS, Chan AHY, Ganesan A (2020) Thirty years of HDAC inhibitors: 2020 insight and hindsight. J Med Chem 63:12460\u201312484. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00830","journal-title":"J Med Chem"},{"key":"11282_CR40","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","volume":"18","author":"T Eckschlager","year":"2017","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18:1414. https:\/\/doi.org\/10.3390\/ijms18071414","journal-title":"Int J Mol Sci"},{"key":"11282_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fonc.2018.00092","volume":"8","author":"A Suraweera","year":"2018","unstructured":"Suraweera A, O\u2019Byrne KJ, Richard DJ (2018) Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol 8:92. https:\/\/doi.org\/10.3389\/fonc.2018.00092","journal-title":"Front Oncol"},{"key":"11282_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/17474086.2017.1280388","volume":"10","author":"JP Laubach","year":"2017","unstructured":"Laubach JP, San-Miguel JF, Hungria V, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Alsina M, Richardson PG (2017) Deacetylase inhibitors: an advance in myeloma therapy. Expert Rev Hematol 10:229\u2013237. https:\/\/doi.org\/10.1080\/17474086.2017.1280388","journal-title":"Expert Rev Hematol"},{"key":"11282_CR43","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ph3092751","volume":"3","author":"S Subramanian","year":"2010","unstructured":"Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL (2010) Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals (Basel) 3:2751\u20132767. https:\/\/doi.org\/10.3390\/ph3092751","journal-title":"Pharmaceuticals (Basel)"},{"key":"11282_CR44","doi-asserted-by":"publisher","first-page":"16532","DOI":"10.1021\/acsomega.3c00222","volume":"8","author":"R Roy","year":"2023","unstructured":"Roy R, Ria T, MahaPatra DR, Sk UH (2023) Single inhibitors versus dual inhibitors: role of HDAC in cancer. ACS Omega 8:16532\u201316544. https:\/\/doi.org\/10.1021\/acsomega.3c00222","journal-title":"ACS Omega"},{"key":"11282_CR45","unstructured":"Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects with Advanced\/Relapsed Solid Tumors. https:\/\/clinicaltrials.gov\/search?term=CUDC-907."},{"key":"11282_CR46","doi-asserted-by":"publisher","first-page":"e0306168","DOI":"10.1371\/journal.pone.0306168","volume":"19","author":"M Jung","year":"2024","unstructured":"Jung M, Nicholas N, Grindrod S, Dritschilo A (2024) Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth. PLoS ONE 19:e0306168. https:\/\/doi.org\/10.1371\/journal.pone.0306168","journal-title":"PLoS ONE"},{"key":"11282_CR47","unstructured":"Onxeo (2017) Combination of a DNA damage response cell cycle checkpoint inhibitors and belinostat for treating cancer. EP3461480A1"},{"key":"11282_CR48","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1021\/acs.jmedchem.4c00090","volume":"67","author":"JL Duan","year":"2024","unstructured":"Duan JL, Wang CC, Yuan YH, Hui Z, Zhang H, Mao ND, Zhang PP, Sun BW, Lin J, Zhang Z, Gao Y, Xie T, Ye XY (2024) Design, synthesis, and structure-activity relationship of novel pyridazinone-based PARP7\/HDACs dual inhibitors for elucidating the relationship between antitumor immunity and HDACs inhibition. J Med Chem 67:4950\u20134976. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00090","journal-title":"J Med Chem"},{"key":"11282_CR49","doi-asserted-by":"publisher","first-page":"2195991","DOI":"10.1080\/14756366.2023.2195991","volume":"38","author":"Y Gao","year":"2023","unstructured":"Gao Y, Duan JL, Dang XW, Yuan YH, Wang Y, He XR, Bai RR, Ye XY, Xie T (2023) Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from \u03b2-elemene scaffold. J Enzyme Inhib Med Chem 38:2195991. https:\/\/doi.org\/10.1080\/14756366.2023.2195991","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11282_CR50","doi-asserted-by":"publisher","first-page":"107973","DOI":"10.1016\/j.bioorg.2024.107973","volume":"153","author":"ND Mao","year":"2024","unstructured":"Mao ND, Xu YY, Yao X, Gao Y, Hui Z, Che H, Wang CC, Lu JS, Yu J, Hu SW, Zhang H, Ye XY (2024) Design, synthesis, and biological evaluation of novel AAK1\/HDACs dual inhibitors against SARS-CoV-2 entry. Bioorg Chem 153:107973. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107973","journal-title":"Bioorg Chem"},{"key":"11282_CR51","doi-asserted-by":"publisher","first-page":"e202200683","DOI":"10.1002\/cmdc.202200683","volume":"18","author":"ND Mao","year":"2023","unstructured":"Mao ND, Gao Y, Dang XW, Duan JL, Hui Z, Che H, Xu YY, Zhang H, He XR, Garrido C, Ye XY (2023) Design, synthesis and biological evaluation of histone deacetylase inhibitors based on pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine scaffolds. ChemMedChem 18:e202200683. https:\/\/doi.org\/10.1002\/cmdc.202200683","journal-title":"ChemMedChem"},{"key":"11282_CR52","doi-asserted-by":"publisher","first-page":"11017","DOI":"10.3390\/ijms241311017","volume":"24","author":"W Wang","year":"2023","unstructured":"Wang W, Di T, Wang W, Jiang H (2023) EGCG, GCG, TFDG, or TSA inhibiting melanin synthesis by downregulating MC1R expression. Int J Mol Sci 24:11017. https:\/\/doi.org\/10.3390\/ijms241311017","journal-title":"Int J Mol Sci"},{"issue":"2","key":"11282_CR53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455\u201361","journal-title":"J Comput Chem"},{"key":"11282_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2025.05.009","author":"G Wang","year":"2025","unstructured":"Wang G, Wang P, Zheng Z, Zhang Q, Xu C, Xu X, Jian L, Zhao Z, Cai G, Wang X (2025) Molecular architecture and inhibition mechanism of human ATR-ATRIP. Sci Bull. https:\/\/doi.org\/10.1016\/j.scib.2025.05.009","journal-title":"Sci Bull"},{"key":"11282_CR55","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/emboj\/18.3.754","volume":"18","author":"C Prodromou","year":"1999","unstructured":"Prodromou C, Siligardi G, O\u2019Brien R, Woolfson DN, Regan L, Panaretou B, Ladbury JE, Piper PW, Pearl LH (1999) Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J 18:754\u2013762. https:\/\/doi.org\/10.1093\/emboj\/18.3.754","journal-title":"EMBO J"},{"key":"11282_CR56","doi-asserted-by":"publisher","first-page":"26729","DOI":"10.1074\/jbc.C500186200","volume":"280","author":"P Bali","year":"2005","unstructured":"Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90. J Biol Chem 280:26729\u201326734","journal-title":"J Biol Chem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11282-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T04:15:30Z","timestamp":1771820130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11282-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["11282"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11282-8","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}